BPRG Bioprogress

BioProgress PLC
18 May 2007


For Immediate Release                                                18 May 2007

               


                BioProgress plc ('BioProgress' or the 'Company')

        Launch of new edible film strip product line "Faststrips" in US

London, UK, 18 May 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM:
BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, today
announces the launch in the US of a range of fast release SoluleavesTM film
strip products. The range is marketed under the brand 'Fast Strips'
(www.faststrips.com) and will be managed within the Nutrifilms marketing
division of the Company's subsidiary Dexo US. The product range is available to
retailers and is initially being introduced to US retailers at the Chain Drug
Marketing Association Virtual Trade Show which runs to 31 May 2007.

The Fast Strips line of products consists of two brand "families". The first is
the "Stay" brand family which is targeted at a traditional grocery or drugstore
customer. The second family, the "Premium" brand family, is a group of
individual brands that will be targeted towards specific demographic groups and
are premium priced. The initial product launch consists of six products in the
"Stay" family and seven products in the "Premium" family. Fast Strips will be
introduced at smaller retail outlets initially and new products will be added to
the line on a quarterly basis.

Richard Trevillion, CEO said:

"The Fast Strips launch demonstrates the breadth and depth of BioProgress's
pipeline. In addition to the Company's prescription only range, the Group now
has a multi-channel offering in one of the fastest growing categories in the US
domestic market."



For further information:

BioProgress Plc                                            + 44 (0) 20 7098 9881
                                                                       
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                                    + 44 (0) 20 7466 5000
                                                                       
Rebecca Skye Dietrich
Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGELTM polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to www.bioprogress.com


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NRAOKOKKFBKDAPD

Bioprogress (LSE:BPRG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Bioprogress (LSE:BPRG)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024